首页> 外文期刊>Biomedical Chromatography: An International Journal Devoted to Research in Chromatographic Methodologies and Their Applications in the Biosciences >A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.
【24h】

A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.

机译:一种同时测定生物基质中右美沙芬及其代谢物右美沙芬,3-甲氧基吗啡喃和3-羟基吗啡喃的经过验证的SIM GC / MS方法,并将其用于体外CYP2D6和CYP3A4抑制研究。

获取原文
获取原文并翻译 | 示例
       

摘要

Dextromethorphan is used as a probe drug for assessing CYP2D6 and CYP3A4 activity in vivo and in vitro. A SIM GC/MS method without derivatization for the simultaneous determination of dextromethorphan and its metabolites, dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan, in human plasma, urine and in vitro incubation matrix was developed and validated. Calibration curves indicated good linearity with a coefficient of variation (r) better than 0.995. The lower limit of quantitation was found to be 10 ng/mL for all analytes in all matrices. Intra-day and inter-day precision for dextromethorphan and its metabolites was better than 9.02 and 9.91%, respectively and accuracy ranged between 91.76 and 106.27%. Recovery for dextromethorphan, its metabolites and internal standard levallorphan was greater than 72.68%. The method has been successfully applied for the in vitro inhibition of metabolism of dextromethorphan by CYP2D6 and CYP3A4 using known inhibitors of CYPs such as quinidine and verapamil.
机译:右美沙芬用作体内和体外评估CYP2D6和CYP3A4活性的探针药物。建立并验证了一种无需衍生化的SIM GC / MS方法,该方法可同时测定人血浆,尿液和体外温育基质中的右美沙芬及其代谢产物右美烷,3-甲氧基吗啡喃和3-羟基吗啡喃。校准曲线表明线性良好,变异系数(r)优于0.995。发现所有基质中所有分析物的定量下限为10 ng / mL。右美沙芬及其代谢产物的日内和日间精密度分别优于9.02和9.91%,准确度在91.76至106.27%之间。右美沙芬,其代谢产物和内标左美洛芬的回收率均大于72.68%。该方法已成功用于使用已知的CYP抑制剂(如奎尼丁和维拉帕米)通过CYP2D6和CYP3A4体外抑制右美沙芬的代谢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号